Experiment 66670
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Ginkgo biloba (GINKGOACEAE) |
| Citation | HAUNS,B: HARING,B: KOHLER,S: MROSS,K: ROBBEN-BATHE,P: UNGER,C:. (1999). PHASE II STUDY WITH 5-FLUOROURACIL AND GINKGO BILOBA EXTRACT (GBE 761 ONC) IN PATIENTS WITH PANCREATIC CANCER.. 49(12) |
| Amount utilized | |
| Compound isolated | |
| Disease | IN A OPEN-LABEL, PROSPECTIVE MONOCENTRIC PHASE II STUDY 48 PATIENTS WITH LOCALLY OR METASTATIC ADVANCED PANCREATIC CANCER WERE TREATED. THE TREATMENT WAS REPEATED EVERY 3 WEEKS UNTIL PROGRESSION. RESPONSE TO THERAPY WAS EVALUATED AFTER 2 AND 4 TREATMENT COURSES. 32 PATIENTS WERE EVALUABLE FOR RESPONSE. PROGRESSIVE DISEASE WAS OBSERVED IN 22 (68.8%) PATIENTS, NO CHANGE IN 7(21.9%) PATIENTS AND PARTIAL RESPONSE IN 3(9.4%) PATIENTS OVERALL RESPONSE = 9.4%). GBE 761 ONC WAS WELL TOLERATED. ADVERSE EVENTS WHICH OCCURRED DURING THE STUDY CONSISTED MAINLY OF MYELOSUPPRESSION AND GASTROINTESTINAL SYMPTOMS AND WERE JUDGED AS 5-FU-RELATED OR CONSISTED OF LIVER TOXICITY, RESPECTIVELY, AND WERE JUDGED AS TUMOR- RELATED. THESE RESULTS SUGGEST A GOOD BENEFIT-RISK RATIO OF THE COMBINATION OF 5-FU AND GBE 761 ONC IN THE TREATMENT OF PANCREATIC CANCER. IN COMPARISON WITH THE RESULTS OF STUDIES WITH EITHER 5-FU OR GEMCITABINE AS SINGEL AGENTS THE COMBINATION OF 5-FU/GBE 761 ONC SHOWS COMPARABLE RESPONSE RATES. THE TOXICITY OF THE 5-FU/GBE 761 ONC COMBINATION WAS LOW. THIS COMBINATION THERAPY THEREFORE WARRANTS FURTHER CLINICAL INVESTIGATION, SUCH AS A CONTROLLED CLINICAL TRIAL AGAINST 5-FU OR GEMCITABINE MONOTHERAPY. A COMMERCIAL PRODUCT, EGB-761, WAS USED. |
| Dose amount | 175.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Extract | TYPE EXT NOT STATED |